US approves first Herceptin biosimilar
Mylan and Biocon’s Ogivri is the first biosimilar of Herceptin to win US approval, for certain breast cancer and metastatic stomach cancers.
Read More
Tag: Ogivri
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
